Efficacy of a spot-on combination of fluralaner plus moxidectin (Bravecto plus) against naturally acquired Sarcoptes scabiei infestation in 10 pet rabbits: Retrospective case series
Abstract
BACKGROUND
Current treatments for sarcoptic mange in rabbits mainly include administration of avermectines every 10-30 days. Recently, a single oral dose of fluralaner has been shown to be effective to treat sarcoptic mange in 12 pet rabbits over a three-month period.
OBJECTIVES
To retrospectively assess the efficacy of a spot-on combination of fluralaner plus moxidectin for the treatment of sarcoptic mange in rabbits.
ANIMALS
Ten client-owned rabbits diagnosed with sarcoptic mange.
MATERIALS AND METHODS
An application of fluralaner plus moxidectin at an average dose of 25 mg/kg and 1.24 mg/kg, respectively, was administered topically once. Parasitological and dermatological examination was carried out weekly for one month and monthly for three months.
RESULTS
The median age at diagnosis was 15 (range 3-48) months. Based on the age of onset, there were three juvenile (<6-month-old) and seven adult-onset cases. Of those, four were generalized (head, feet and/or genital area) and six were localized form (head only). The combination of fluralaner plus moxidectin resulted in 100% eradication of mites and complete resolution of all skin lesions within 21 days. Recurrence was not observed 90 days post-treatment. Relapse was not observed in one case followed up for a further four months and two rabbits followed up for a further six months. The other pets were lost to follow-up.
CONCLUSIONS AND CLINICAL RELEVANCE
These results indicated that a single dose of a formulation containing…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.